Biosynexus Incorporated
Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in the setting of the neonatal intensive care unit (NICU). The company has two additional product candidates: lysostaphin for the treatment of life threatening staphylococcal infections and nisin a topical cream for treating serious skin infections. Biosynexus' mission is bringing products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
11 to 50
headcount range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Biosynexus Incorporated
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Biosynexus Incorporated
2 distinct titles indexed · top 2 shown.
- 1corporate administrator
- 1customer services
Sign up to unlock all 2 contacts at Biosynexus Incorporated
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Biosynexus Incorporated
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.